MichaelBrinesMDPhD
Endocrinology • Guilford, CTDiabetes, Lipid Metabolism
Chief Scientific and Medical Officer
Dr. Brines is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2488 Boston Post Rd
Guilford, CT 06437Phone+1 203-204-6130
Education & Training
Yale-New Haven Medical CenterResidency, Internal Medicine, 1984 - 1986
Yale School of MedicineClass of 1983
Certifications & Licensure
CT State Medical License 1986 - 2020
Publications & Presentations
PubMed
- 326 citationsAsialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo.Serhat Erbayraktar, Giovanni Grasso, Alessandra Sfacteria, Qiao wen Xie, Thomas Coleman
Proceedings of the National Academy of Sciences of the United States of America. 2003-05-27 - 1138 citationsErythropoietin crosses the blood-brain barrier to protect against experimental brain injury.Michael Brines, Pietro Ghezzi, Sonja Keenan, Davide Agnello, Nihal C. de Lanerolle
Proceedings of the National Academy of Sciences of the United States of America. 2000-09-12 - 101 citationsARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Michael Brines, Ann Dunne, Monique van Velzen, P.L. Proto, Claes-Göran Östenson
Molecular Medicine. 2014-01-01
Press Mentions
ARA 290 Obtains European Union Orphan Drug Designation for Prevention of Graft Loss in Pancreatic Islet TransplantationNovember 28th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
